🚀 VC round data is live in beta, check it out!
Pangaea Oncology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Pangaea Oncology and similar public comparables like LENSAR, FluoGuide, Sensus Healthcare, Applied BioCode and more.
Pangaea Oncology Overview
About Pangaea Oncology
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
Founded
2007
HQ
Employees
53
Website
Financials (FY)
EV
$75M
Pangaea Oncology Financials
Pangaea Oncology reported last fiscal year revenue of $17M and EBITDA of $1M.
In the same fiscal year, Pangaea Oncology generated $17M in gross profit, $1M in EBITDA, and had net loss of ($1M).
Pangaea Oncology P&L
In the most recent fiscal year, Pangaea Oncology reported revenue of $17M and EBITDA of $1M.
Pangaea Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $17M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $17M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 100% | XXX | XXX | XXX |
| EBITDA | — | XXX | $1M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 8% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (14%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($1M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (8%) | XXX | XXX | XXX |
| Net Debt | — | — | $3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pangaea Oncology Stock Performance
Pangaea Oncology has current market cap of $72M, and enterprise value of $75M.
Market Cap Evolution
Pangaea Oncology's stock price is $2.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $75M | $72M | 0.0% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPangaea Oncology Valuation Multiples
Pangaea Oncology trades at 4.5x EV/Revenue multiple, and 54.0x EV/EBITDA.
Pangaea Oncology Financial Valuation Multiples
As of April 20, 2026, Pangaea Oncology has market cap of $72M and EV of $75M.
Equity research analysts estimate Pangaea Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pangaea Oncology has a P/E ratio of (52.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $72M | XXX | $72M | XXX | XXX | XXX |
| EV (current) | $75M | XXX | $75M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 54.0x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (32.1x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.5x | XXX | XXX | XXX |
| P/E | — | XXX | (52.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (12.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Pangaea Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Pangaea Oncology Margins & Growth Rates
Pangaea Oncology's revenue in the last fiscal year grew by 78%.
Pangaea Oncology's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.
Pangaea Oncology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 78% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (176%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 29% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 114% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Pangaea Oncology Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pangaea Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| LENSAR | XXX | XXX | XXX | XXX | XXX | XXX |
| FluoGuide | XXX | XXX | XXX | XXX | XXX | XXX |
| Sensus Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Applied BioCode | XXX | XXX | XXX | XXX | XXX | XXX |
| Creo Medical Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pangaea Oncology M&A Activity
Pangaea Oncology acquired XXX companies to date.
Last acquisition by Pangaea Oncology was on XXXXXXXX, XXXXX. Pangaea Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Pangaea Oncology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPangaea Oncology Investment Activity
Pangaea Oncology invested in XXX companies to date.
Pangaea Oncology made its latest investment on XXXXXXXX, XXXXX. Pangaea Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Pangaea Oncology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Pangaea Oncology
| When was Pangaea Oncology founded? | Pangaea Oncology was founded in 2007. |
| Where is Pangaea Oncology headquartered? | Pangaea Oncology is headquartered in Spain. |
| How many employees does Pangaea Oncology have? | As of today, Pangaea Oncology has over 53 employees. |
| Is Pangaea Oncology publicly listed? | Yes, Pangaea Oncology is a public company listed on Bolsa de Madrid. |
| What is the stock symbol of Pangaea Oncology? | Pangaea Oncology trades under PANG ticker. |
| When did Pangaea Oncology go public? | Pangaea Oncology went public in 2016. |
| Who are competitors of Pangaea Oncology? | Pangaea Oncology main competitors are LENSAR, FluoGuide, Sensus Healthcare, Applied BioCode. |
| What is the current market cap of Pangaea Oncology? | Pangaea Oncology's current market cap is $72M. |
| What is the current revenue of Pangaea Oncology? | Pangaea Oncology's last fiscal year revenue is $17M. |
| What is the current EV/Revenue multiple of Pangaea Oncology? | Current revenue multiple of Pangaea Oncology is 4.5x. |
| Is Pangaea Oncology profitable? | No, Pangaea Oncology is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.